|
1
|
Mobus V, Jackisch C, Luck HJ, du Bois A,
Thomssen C, Kuhn W, Nitz U, Schneeweiss A, Huober J, Harbeck N, et
al: Ten-year results of intense dose-dense chemotherapy show
superior survival compared with a conventional schedule in
high-risk primary breast cancer: Final results of AGO phase III
iddEPC trial. Ann Oncol. 29:178–185. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mobus V, von Minckwitz G, Jackisch C, Luck
HJ, Schneeweiss A, Tesch H, Elling D, Harbeck N, Conrad B, Fehm T,
et al: German adjuvant intergroup Node-positive Study (GAIN): A
phase III trial comparing two dose-dense regimens (iddEPC versus
ddEC-PwX) in high-risk early breast cancer patients. Ann Oncol.
28:1803–1810. 2017.PubMed/NCBI
|
|
3
|
Lambertini M, Ceppi M, Cognetti F,
Cavazzini G, De Lurentiis M, De Placido S, Michelotti A, Bisagni G,
Durando A, Valle E, et al: Dose-dense adjuvant chemotherapy in
premenopausal breast cancer patients: A pooled analysis of the MIG1
and GIM2 phase III studies. Eur J Cancer. 71:34–42. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Foukakis T, von Minckwiz G, Bengtsson NO,
Brandberg Y, Wallberg B, Fornander T, Mineritsch B, Schmatloch S,
Singer CF, Steger G, et al: Effect of tailored dose-dense
chemotherapy vs standard 3-weekly adjuvant chemotherapy on
recurrence-free survival among women with high-risk early breast
cancer: A Randomized Clinical Trial. JAMA. 316:1888–1896. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Del Mastro L, De Placido S, Bruzi P, De
Laurentiis M, Boni C, Cavazzini G, Durando A, Turletti A, Nisticò
C, Valle E, et al: Fluorouracil and dose-dense chemotherapy in
adjuvant treatment of patients with early-stage breast cancer: An
open-label, 2 × 2 factorial, randomised phase 3 trial. Lancet.
385:1863–1872. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aapro M, Boccia R, Leonard R, Camps C,
Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, et al:
Refining the role of pegfilgrastim (a long-acting G-CSF) for
prevention of chemotherapy-induced febrile neutropenia: Consensus
guidance recommendations. Support Care Cancer. 25:3295–3304. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vehreschild JJ, Bohme A, Cornely OA, Kahl
C, Karthaus M, Kreuzer KA, Maschmeyer G, Mousset S, Ossendorf V,
Penack O, et al: Prophylaxis of infectious complications with
colony-stimulating factors in adult cancer patients undergoing
chemotherapy-evidence-based guidelines from the infectious diseases
working party AGIHO of the German society for haematology and
medical oncology (DGHO). Ann Oncol. 25:1709–1718. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smith TJ, Bohlke K, Lyman GH, Carson KR,
Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB,
Perkins CL, Somlo G, et al: Recommendations for the Use of WBC
Growth Factors: American Society of Clinical Oncology Clinical
Practice Guideline Update. J Clin Oncol. 33:3199–212. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aapro MS, Bohlius J, Cameron DA, Dal Lago
L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC,
Walewski J, Weber DC, et al: 2010 update of EORTC guidelines for
the use of granulocyte-colony stimulating factor to reduce the
incidence of chemotherapy-induced febrile neutropenia in adult
patients with lymphoproliferative disorders and solid tumours. Eur
J Cancer. 47:8–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Crawford J, Becker PS, Armitage JO,
Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I,
Griffiths EA, Hough S, et al: Myeloid Growth Factors, Version
2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr
Canc Netw. 15:1520–1541. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Green MD, Koelbl H, Baselga J, Galid A,
Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR,
et al: A randomized double-blind multicenter phase III study of
fixed-dose single-administration pegfilgrastim versus daily
filgrastim in patients receiving myelosuppressive chemotherapy. Ann
Oncols. 14:29–35. 2003. View Article : Google Scholar
|
|
12
|
Grigg A, Solal-Celigny P, Hoskin P, Taylor
K, McMillan A, Forstpointner R, Bacon P, Renwick J and Hiddemann W;
International Study Group, : Open-label, randomized study of
pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in
elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma.
44:1503–1508. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Holmes FA, Jones SE, O'Shaughnessy J,
Vukelja S, George T, Savin M, Richards D, Glaspy J, Meza L, Cohen
G, et al: Comparable efficacy and safety profiles of once-per-cycle
pegfilgrastim and daily injection filgrastim in
chemotherapy-induced neutropenia: A multicenter dose-finding study
in women with breast cancer. Ann Oncol. 13:903–909. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Holmes FA, O'Shaughnessy JA, Vukelja S,
Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer
I, et al: Blinded, randomized, multicenter study to evaluate single
administration pegfilgrastim once per cycle versus daily filgrastim
as an adjunct to chemotherapy in patients with high-risk stage II
or stage III/IV breast cancer. J Clin Oncol. 20:727–731. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vose JM, Crump M, Lazarus H, Emmanouilides
C, Schenkein D, Moore J, Moore J, Frankel S, Flinn I, Lovelace W,
et al: Randomized, multicenter, open-label study of pegfilgrastim
compared with daily filgrastim after chemotherapy for lymphoma. J
Clin Oncol. 21:514–519. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang W, Jiang Z, Wang L, Li C and Xia J:
An open-label, randomized, multicenter dose-finding study of
once-per-cycle pegfilgrastim versus daily filgrastim in Chinese
breast cancer patients receiving TAC chemotherapy. Med Oncol.
32:1472015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cooper KL, Madan J, Whyte S, Stevenson MD
and Akehurst RL: Granulocyte colony-stimulating factors for febrile
neutropenia prophylaxis following chemotherapy: Systematic review
and meta-analysis. BMC Cancer. 11:4042011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pinto L, Liu Z, Doan Q, Bernal M, Dubois R
and Lyman G: Comparison of pegfilgrastim with filgrastim on febrile
neutropenia, grade IV neutropenia and bone pain: A meta-analysis of
randomized controlled trials. Curr Med Res Opin. 23:2283–2295.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Masuda N, Tokuda Y, Nakamura S, Shimazaki
R, Ito Y and Tamura K: Dose response of pegfilgrastim in Japanese
breast cancer patients receiving six cycles of docetaxel,
doxorubicin, and cyclophosphamide therapy: A randomized controlled
trial. Support Care Cancer. 23:2891–2898. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kosaka Y, Rai Y, Masuda N, Takano T, Saeki
T, Nakamura S, Shimazaki R, Ito Y, Tokuda Y and Tamura K: Phase III
placebo-controlled, double-blind, randomized trial of pegfilgrastim
to reduce the risk of febrile neutropenia in breast cancer patients
receiving docetaxel/cyclophosphamide chemotherapy. Support Care
Cancer. 23:1137–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pawloski PA, Larsen M, Thoresen A and
Giordana MD: Pegfilgrastim use and bone pain: A cohort study of
community-based cancer patients. J Oncol Pharm Pract. 22:423–429.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Moukharskaya J, Abrams DM, Ashikaga T,
Khan F, Schwartz J, Wilson K, Verschraegen C, Openshaw T, Valentine
J, Eneman J, et al: Randomized phase II study of loratadine for the
prevention of bone pain caused by pegfilgrastim. Support Care
Cancer. 24:3085–3093. 2016.PubMed/NCBI
|
|
23
|
Union for International Cancer Control-TNM
classification. 8th. https://www.uicc.org/July 17–2019
|
|
24
|
Untch M, Jackisch C, Schneeweiss A, Conrad
B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S,
Hilfrich J, et al: Nab-paclitaxel versus solvent-based paclitaxel
in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG
69): A randomised, phase 3 trial. Lancet Oncol. 17:345–356. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shimada H, Ueda S, Saeki T, Shigekawa T,
Takeuchi H, Hirokawa E, Sugitani I, Sugiyama M, Takahashi T,
Matsuura K, et al: Neoadjuvant triweekly nanoparticle albumin-bound
paclitaxel followed by epirubicin and cyclophosphamide for Stage
II/III HER2-negative breast cancer: Evaluation of efficacy and
safety. Jpn J Clin Oncol. 45:642–649. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saito M, Aogi K, Sekine I, Yoshizawa H,
Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T and Mitsuhashi S:
Palonosetron plus dexamethasone versus granisetron plus
dexamethasone for prevention of nausea and vomiting during
chemotherapy: A double-blind, double-dummy, randomised, comparative
phase III trial. Lancet Oncol. 10:115–124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsuyuki S, Senda N, Kanng Y, Yamaguchi A,
Yoshibayashi H, Kikawa Y, Katakami N, Kato H, Hashimoto T, Okuno T,
et al: Evaluation of the effect of compression therapy using
surgical gloves on nanoparticle albumin-bound paclitaxel-induced
peripheral neuropathy: A phase II multicenter study by the Kamigata
Breast Cancer Study Group. Breast Cancer Res Treat. 160:61–67.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lambertini M, Del Mastro L, Bellodi A and
Pronzato P: The five ‘Ws’ for bone pain due to the administration
of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol
Hematol. 89:112–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hamilton JA: Colony-stimulating factors in
inflammation and autoimmunity. Nat Rev Immunol. 8:533–544. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stosser S, Schweizerhof M and Kuner R:
Hematopoietic colony-stimulating factors: New players in
tumor-nerve interactions. J Mol Med (Berl). 89:321–329. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Package insert, . Neulasta
(pegfilgrastim). Thousand Oaks, CA, Amgen. September 15–2005,
https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/pegfamg013102LB.pdf#search=%27Package+insert.+Neulasta+%28pegfilgrastim%29.+Thousand+Oaks%2C+CA%3A+Amgen%2C+September+15%2C+2005.%27July
17–2019
|
|
32
|
Rheingold SD and Lange BJ: Oncogenic
emergencies. Principkes and Practice of Pediatric Oncology. 4th.
Pizzo PA and Poplack DG: Philadelphia: Lippincott Williams &
Wilkins; pp. 1177–1203. 2002
|
|
33
|
Schirm S, Engel C, Loibl S, Loeffler M and
Scholz M: Model-based optimization of G-CSF treatment during
cytotoxic chemotherapy. J Cancer Res Clin Oncol. 144:343–358. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ishiguro H, Kitano T, Yoshibayash i, Toi
M, Ueno T, Yasuda H, Yanagihara K, Garbo CL and Fukushima M:
Prolonged neutropenia after dose-dense chemotherapy with
pegfilgrastim. Ann Oncol. 19:1019–1020. 2008. View Article : Google Scholar : PubMed/NCBI
|
